首页> 外文期刊>Der Pharmacia Lettre >Development and characterization of ketoprofen solid dispersion incorporated topical gels
【24h】

Development and characterization of ketoprofen solid dispersion incorporated topical gels

机译:酮洛芬固体分散体掺入局部凝胶的开发和表征

获取原文
           

摘要

The present work aims to increase the therapeutic effectiveness of ketoprofen by increasing its transdermal permeation, via solid dispersion incorporated in gel. 2-hydroxy propyl beta cyclodextrins (HPβ-CD) and β- cyclodextrin (β-CD) were used as carriers and carbopol 940 was the gelling agent. Eight solid dispersion formulations of ketoprofen were prepared using different drug: polymer ratios viz. 1:0.5, 1:1, 1:2, and 1:3 for 2- HPβ-CD and β cyclodextrin using the solvent evaporation method. The formulation of solid dispersion by solvent evaporation method is introduced to reduce the drug particle size and hence increase the dissolution rate. These dispersions were characterized with the help of FT-IR, DSC and X-ray diffraction studies. The optimized solid dispersion of ketoprofen was incorporated into gel and was compared with penetration enhancers. The formulations were analyzed to determine their pH, spreadability, viscosity, and in vitro drug release. The formulation with 1:0.5 SDK (drug: HPβCD) was incorporated in carbopol gel, and produced 98.32 % drug release compared to solid dispersion of ketoprofen with menthol (SDKM5%), which produced 96.26% drug release. In ex vivo studies, SDK and SDKM5% formulations gave 94.37% and 92.26% drug release respectively within 24 h. The percent inhibitions of the edema formation by the gels were in the range of 19.63% to 69.65%, and the maximum inhibition was shown by the SDK formulation. Therefore, SDK formulation incorporated in gel produced better results than other formulations prepared with permeation enhancers. Stability studies conducted for SDK incorporated gel.
机译:本发明的目的是通过掺入凝胶中的固体分散体,通过增加其透皮渗透性来提高酮洛芬的治疗效果。将2-羟丙基β-环糊精(HPβ-CD)和β-环糊精(β-CD)用作载体,而carbopol 940是胶凝剂。使用不同的药物:聚合物比率制备八种酮洛芬的固体分散体制剂。对于2-HPβ-CD和β环糊精,采用溶剂蒸发法的1:0.5、1:1、1:2和1:3。引入通过溶剂蒸发法的固体分散体制剂以减小药物粒径并因此增加溶解速率。借助FT-IR,DSC和X射线衍射研究对这些分散体进行了表征。将酮洛芬的优化固体分散体掺入凝胶中,并与渗透促进剂进行比较。对制剂进行分析以确定其pH,铺展性,粘度和体外药物释放。将具有1:0.5 SDK(药物:HPβCD)的制剂掺入卡波姆凝胶中,与酮洛芬与薄荷醇的固体分散体(SDKM5%)相比,产生98.32%的药物释放,而后者产生96.26%的药物释放。在离体研究中,SDK和SDKM5%制剂在24小时内分别释放了94.37%和92.26%。凝胶对水肿形成的抑制百分率在19.63%至69.65%的范围内,SDK配方显示出最大的抑制作用。因此,凝胶中掺入的SDK制剂比用渗透促进剂制备的其他制剂产生更好的结果。对包含SDK的凝胶进行稳定性研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号